'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009.

ACTRIMS-ECTRIMS MSBoston 2014: Oral Presentations

s Multiple sclerosis Journal 2014; 20: (S1) 3–13 10.1177/1352458514547850 © 2014 SAGE Publications ACTRIMS-ECTRIMS MSBoston 2014

Emerging oral therapies for Multiple Sclerosis. Report of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Trial Designs Likely to Meet Valid Long-Term Alzheimer's Disease Progression Effects: Learning from the Past, Preparing for the Future

The International Society for CNS Clinical Trials and Methodology (ISCTM) held its 4th Annual Autumn Conference in Toronto, Ontario, October 6-7, 2008. The purpose of the present report is to provide an overview of one of the sessions at the conference which focused on the designs and methodologies to be applied in clinical trials of new treatments for Alzheimer's disease (AD) with purported "d...

Cost-Effectiveness of New Therapies for Multiple Sclerosis In Spain.

1. Gold R, et al. Multiple Sclerosis Journal 2015;21(1):57-66. 2. Fernández O, et al. ECTRIMS 2014; P065. [Cited 01/06/2015]. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2014/ACTRIMSECTRIMS2014/63772/undefined 3. O’Connor P, et al. N Engl J Med 2011;365:1293-303. 4. Miller AE, et al. J Neurol 2014;261:1781-1788. 5. Vermersch P, et al. Mult Scler 2014;20(6):705-16. 6. Polman C...

O 14: Differentiating Demyelinating Disorders of the Central Nervous System – a Focus on Multiple Sclerosis and Neuromyelitis-Optica Spectrum Disorders

Significant advances have been made in diagnosis and therapy of demyelinating disorders of the central nervous system. The most common entities of this disorders in adults – multiple sclerosis and neuromyelitis optica were initially thought to be different phenotypes of more or less the same disease. During the last ten years, this view was subsequently changed and the term neuromyelitis ...